Brent K Hollenbeck
Overview
Explore the profile of Brent K Hollenbeck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
330
Citations
4356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ying M, Shay A, Hollingsworth J, Shahinian V, Hollenbeck B
Health Serv Res
. 2025 Mar;
:e14597.
PMID: 40083132
Objective: To evaluate the early effects of Pathways to Success implementation on utilization, as measured by quarterly price-standardized Medicare spending per beneficiary. Study Setting And Design: This study was a...
2.
Srivastava A, Kaufman S, Shay A, Oerline M, Liu X, Van Til M, et al.
JAMA Netw Open
. 2025 Jan;
8(1):e2453658.
PMID: 39775806
Importance: Active surveillance in men with less aggressive prostate cancer is inconsistently used despite clinical guidelines. Renumeration generally favors treatment over conservative management and may contribute to the variable adoption...
3.
Faraj K, Kaufman S, Oerline M, Dall C, Srivastava A, Caram M, et al.
Cancer Med
. 2024 Dec;
14(1):e70552.
PMID: 39739625
Introduction: Oral targeted therapies are a standard of care for men with advanced prostate cancer. However, these therapies are expensive, which may be a barrier to some, particularly the most...
4.
Dall C, Liu X, Faraj K, Srivastava A, Kaufman S, Hartman N, et al.
Cancer Med
. 2024 Dec;
13(23):e70436.
PMID: 39624952
Introduction And Objectives: Prior work has demonstrated racial disparities in surgical outcomes for solid organ cancers. We sought to assess the relationship between hospital quality and racial disparities in achievement...
5.
Maganty A, Kaufman S, Oerline M, Faraj K, Caram M, Ryan A, et al.
Urology
. 2024 Nov;
196:137-144.
PMID: 39581508
Objective: To examine the relationship between market dynamics, in the form of commercial prices paid to urologists, and utilization of services, as measured by Medicare spending, in men with newly...
6.
Srivastava A, Liu X, Maganty A, Kaufman S, Shay A, Oerline M, et al.
Cancer
. 2024 Nov;
131(1):e35633.
PMID: 39501423
Background: For men with prostate cancer, there is substantial variation in the use of conservative management, such as active surveillance. Commercial prices, which vary across urology practices, may afford incentives...
7.
Abusamra S, Solorzano M, Quarles J, Luke M, Patel M, Vince Jr R, et al.
Urol Pract
. 2024 Oct;
12(1):63-72.
PMID: 39383006
Introduction: There is increasing awareness that patients with prostate cancer frequently harbor germline variants that may carry important implications for them and their family members. Given the variable clinical guidelines,...
8.
Morgan T, Daignault-Newton S, Spratt D, Dunn R, Dunn R, Singhal U, et al.
Eur Urol
. 2024 Oct;
87(2):228-237.
PMID: 39379238
Background And Objective: Decipher is a tissue-based genomic classifier (GC) developed and validated in the post-radical prostatectomy (RP) setting as a predictor of metastasis. We conducted a prospective randomized controlled...
9.
Srivastava A, Hollenbeck B
JAMA Netw Open
. 2024 Sep;
7(9):e2434114.
PMID: 39283643
No abstract available.
10.
Faraj K, Oerline M, Kaufman S, Dall C, Srivastava A, Caram M, et al.
Urol Pract
. 2024 Aug;
11(6):931-938.
PMID: 39196717
Introduction: The use of expensive oral targeted agents for advanced prostate cancer can be influenced by those who stand to gain from their use. The 340B drug pricing program allows...